Skip to main content
PMC home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Aug 17.
Published in final edited form as: Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, Katherine E Hutchinson, Daniel G Stover, Kyung-Min Lee, Luis J Schwarz, Jennifer M Giltnane, Monica V Estrada, Valerie M Jansen, Alberto Servetto, Joaquín Gavilá, J Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mόnica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L Arteaga
PMCID: PMC6697080  NIHMSID: NIHMS1038662  PMID: 30770490

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Reference

  • 1.Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, et al. ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors. Clin Cancer Res 2018;24:2517–29. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES